

# Klemens Budde

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6190154/publications.pdf>

Version: 2024-02-01

566  
papers

25,224  
citations

8181

76  
h-index

11607

135  
g-index

622  
all docs

622  
docs citations

622  
times ranked

19433  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of severity of delayed graft function in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 973-981.	0.7	8
2	Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients. <i>Cardiology Journal</i> , 2022, 29, 263-271.	1.2	2
3	Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. <i>Journal of Critical Care</i> , 2022, 67, 126-131.	2.2	6
4	Barriers to online consultation in nephrological care: An online-survey among nephrologists. <i>Clinical Nephrology</i> , 2022, 97, 129-130.	0.7	0
5	Kidney Perfusion in Contrast-Enhanced Ultrasound (CEUS) Correlates with Renal Function in Living Kidney Donors. <i>Journal of Clinical Medicine</i> , 2022, 11, 791.	2.4	4
6	Determination of unacceptable <sc>HLA</sc> antigen mismatches in kidney transplant recipients. <i>Hla</i> , 2022, 100, 3-17.	0.6	9
7	Authorsâ€™ Reply: SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 870-871.	6.1	0
8	Influence of Belatacept- vs. CNI-Based Immunosuppression on Vascular Stiffness and Body Composition. <i>Journal of Clinical Medicine</i> , 2022, 11, 1219.	2.4	0
9	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccinationâ€™specific humoral and cellular immunity in kidney transplant recipients. <i>JCI Insight</i> , 2022, 7, .	5.0	62
10	Body Mass Index Thresholds and the Use of Bariatric Surgery in the Field of Kidney Transplantation in Germany. <i>Obesity Surgery</i> , 2022, 32, 1641-1648.	2.1	6
11	Predictors of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Patients: Baseline Characteristics, Immunosuppression, and the Role of IMPDH Monitoring. <i>Journal of Clinical Medicine</i> , 2022, 11, 1697.	2.4	9
12	Impact of COVID-19 on Global Kidney Transplantation Service Delivery: Interim Report. <i>Transplant International</i> , 2022, 35, 10302.	1.6	4
13	Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. <i>Trials</i> , 2022, 23, 270.	1.6	8
14	Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatmentâ€™A Single Center Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 199.	2.4	4
15	The mTOR inhibitor Rapamycin protects from premature cellular senescence early after experimental kidney transplantation. <i>PLoS ONE</i> , 2022, 17, e0266319.	2.5	6
16	Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients. <i>Transplant International</i> , 2022, 35, 10109.	1.6	5
17	Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2022, 11, 2565.	2.4	52
18	Poor Outcomes in Patients With Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	3

#	ARTICLE	IF	CITATIONS
19	Declining Course of Humoral Immune Response in Initially Responding Kidney Transplant Recipients after Repeated SARS-CoV-2 Vaccination. <i>Journal of Clinical Medicine</i> , 2022, 11, 3291.	2.4	1
20	Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 151-167.	2.4	13
21	Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity. <i>American Journal of Transplantation</i> , 2021, 21, 1391-1401.	4.7	30
22	eHealth in transplantation. <i>Transplant International</i> , 2021, 34, 16-26.	1.6	24
23	The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective single-center cohort study. <i>Transplant International</i> , 2021, 34, 259-271.	1.6	4
24	Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 14-26.	2.0	8
25	A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 708-722.	6.1	101
26	Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging. <i>American Journal of Transplantation</i> , 2021, 21, 1725-1739.	4.7	9
27	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. <i>PLoS ONE</i> , 2021, 16, e0245880.	2.5	9
28	Assertion Detection in Clinical Notes: Medical Language Models to the Rescue?. , 2021, , .		9
29	STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients – An Observational Study in Germany. <i>Current Clinical Pharmacology</i> , 2021, 16, 357-368.	0.6	0
30	What happens after graft loss? A large, long-term, single-center observation. <i>Transplant International</i> , 2021, 34, 732-742.	1.6	6
31	Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. <i>Journal of Clinical Medicine</i> , 2021, 10, 510.	2.4	5
32	The underestimated burden of monogenic kidney disease in adults waitlisted for kidney transplantation. <i>Genetics in Medicine</i> , 2021, 23, 1219-1224.	2.4	28
33	TuberOus SCLerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2021, 12, 630378.	2.4	10
34	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3851-3862.	2.4	6
35	A 2020 Banff Antibody-mediated Injury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation – a cohort study. <i>Transplant International</i> , 2021, 34, 488-498.	1.6	15
36	Exploring the Complexity of Death-Censored Kidney Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1513-1526.	6.1	67

#	ARTICLE	IF	CITATIONS
37	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	2.0	89
38	TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	24
39	Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	4
40	Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. <i>Kidney International Reports</i> , 2021, 6, 905-915.	0.8	22
41	MO938PATIENT SURVIVAL AFTER LIVING DONOR KIDNEY DONATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
42	Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs. <i>Journal of Clinical Medicine</i> , 2021, 10, 2099.	2.4	22
43	Undoubtedly, kidney transplant recipients have a higher mortality due to COVID-19 disease compared to the general population. <i>Transplant International</i> , 2021, 34, 769-771.	1.6	17
44	MO105TELEMEDICAL SURVEILLANCE AND OPTIMIZED TREATMENT OF BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
45	Kidney graft function and arterial stiffness in renal transplant recipients. <i>Acta Biochimica Polonica</i> , 2021, 68, 331-339.	0.5	1
46	MO943IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
47	Effectiveness of interventions in patients who develop graft nephrolithiasis after kidney transplantation: A systematic review. <i>European Urology</i> , 2021, 79, S466-S467.	1.9	0
48	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	11.9	223
49	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698.	4.8	52
50	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the Tuberous Sclerosis registry to increase disease awareness (TOSCA). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 301.	2.7	15
51	Early Postoperative Basal Insulin Therapy versus Standard of Care for the Prevention of Diabetes Mellitus after Kidney Transplantation: A Multicenter Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2083-2098.	6.1	21
52	Anti-Interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. <i>Transplant International</i> , 2021, 34, 1542-1552.	1.6	7
53	Impact of Early Pancreatic Graft Loss on Outcome after Simultaneous Pancreas-Kidney Transplantation (SPKT) – A Landmark Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3237.	2.4	7
54	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	212

#	ARTICLE	IF	CITATIONS
55	Clinicopathologic Features and Risk Factors of Proteinuria in Transplant Glomerulopathy. <i>Frontiers in Medicine</i> , 2021, 8, 666319.	2.6	1
56	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. <i>Clinical Immunology</i> , 2021, 229, 108792.	3.2	6
57	Does the Side Matter? A Retrospective Cohort Study Comparing Left and Right Pure Laparoscopic Donor Nephrectomies. <i>Urologia Internationalis</i> , 2021, 105, 1076-1084.	1.3	3
58	Low-dose rapamycin does not impair vascular integrity and tubular regeneration after kidney transplantation in rats. <i>Scientific Reports</i> , 2021, 11, 16270.	3.3	1
59	Analysis of Factors Affecting Employment Status of Kidney Transplant Recipients in Selected European Union Member States. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10284.	2.6	1
60	Updated International Tuberos Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	2.1	230
61	Sirolimus in renal transplant recipients with malignancies in Germany. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2047-2058.	2.9	9
62	Inosine 5- $\alpha$ -Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients. <i>Transplantation</i> , 2021, 105, 916-927.	1.0	7
63	Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. <i>Journal of Clinical Medicine</i> , 2021, 10, 89.	2.4	5
64	Clinical Outcome Prediction from Admission Notes using Self-Supervised Knowledge Integration. , 2021, , .		18
65	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	6.1	82
66	Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11793.	4.1	14
67	Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , 2021, 7, e778.	1.6	15
68	Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3252-3264.	6.1	41
69	Outcomes of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program with A Focus on Recipients $\geq 75$ Years. <i>Journal of Clinical Medicine</i> , 2021, 10, 5633.	2.4	5
70	Predictors of graft survival at diagnosis of antibody-mediated renal allograft rejection: a retrospective single-center cohort study. <i>Transplant International</i> , 2020, 33, 149-160.	1.6	5
71	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	1.0	172
72	Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients. <i>Transplant Immunology</i> , 2020, 63, 101333.	1.2	4

#	ARTICLE	IF	CITATIONS
73	ANTI-IL-6 ANTIBODY CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION – MOLECULAR REBOUND PHENOMENA UNDER IL-6 BLOCKADE?. <i>Transplantation</i> , 2020, 104, S67-S67.	1.0	2
74	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 24.	3.1	16
75	Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept. <i>BMC Nephrology</i> , 2020, 21, 354.	1.8	12
76	Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMI. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 787-793.	2.0	8
77	Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphocele. <i>Journal of Clinical Medicine</i> , 2020, 9, 2841.	2.4	3
78	Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center. <i>Journal of Clinical Medicine</i> , 2020, 9, 3401.	2.4	13
79	OBESITY, FAT TISSUE, CELL MEMBRANE INTEGRITY PARAMETERS AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
80	ANALYZING CAUSES FOR DEATH-CENSORED ALLOGRAFT FAILURE IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2020, 104, S69-S70.	1.0	0
81	Is a Retroaortic Vein a Risk Factor in Laparoscopic Living Donor Nephrectomy?. <i>Urologia Internationalis</i> , 2020, 104, 641-645.	1.3	4
82	Robot-Assisted versus Laparoscopic Donor Nephrectomy: A Comparison of 250 Cases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1610.	2.4	15
83	Obesity, Fat Tissue Parameters, and Arterial Stiffness in Renal Transplant Recipients. <i>Transplantation Proceedings</i> , 2020, 52, 2341-2346.	0.6	8
84	Should We Perform Old-For-Old Kidney Transplantation during the COVID-19 Pandemic? The Risk for Post-Operative Intensive Stay. <i>Journal of Clinical Medicine</i> , 2020, 9, 1835.	2.4	3
85	Determinants of Successful Use of Sirolimus in Renal Transplant Patients. <i>Transplantation Proceedings</i> , 2020, 52, 3103-3111.	0.6	3
86	Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: A retrospective study. <i>Journal of Critical Care</i> , 2020, 58, 1-5.	2.2	4
87	Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. <i>Transplantation Reviews</i> , 2020, 34, 100531.	2.9	17
88	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. <i>Kidney International</i> , 2020, 98, 1044-1052.	5.2	103
89	Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. <i>Annals of Transplantation</i> , 2020, 25, e923278.	0.9	6
90	De-novo malignancies after kidney transplantation: A long-term observational study. <i>PLoS ONE</i> , 2020, 15, e0242805.	2.5	9

#	ARTICLE	IF	CITATIONS
91	The The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients – a cross-sectional prospective observational clinical study. <i>Acta Biochimica Polonica</i> , 2020, 67, 613-622.	0.5	2
92	IMPACT OF NON-ACTIVE HEPATITIS B ON PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 2020, 104, S314-S315.	1.0	0
93	NT-PRO BNP, VISCERAL FAT AREA, CELL MEMBRANE INTEGRITY AND ARTERIAL STIFFNESS IN RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 2020, 104, S600-S600.	1.0	0
94	THREE-MONTH RESULTS OF A PHASE 2 TRIAL EVALUATING CLAZAKIZUMAB IN LATE ANTIBODY-MEDIATED REJECTION – EARLY IMPACT OF IL-6 BLOCKADE ON DONOR-SPECIFIC ANTIBODY LEVELS, REJECTION MORPHOLOGY AND GENE EXPRESSION. <i>Transplantation</i> , 2020, 104, S355-S355.	1.0	0
95	Information Extraction Models for German Clinical Text. , 2020, , .		4
96	Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. <i>American Journal of Transplantation</i> , 2019, 19, 123-131.	4.7	35
97	Perioperative antibiotic prophylaxis in renal transplantation: a single-center comparison between two regimens and a brief survey among the Eurotransplant renal transplantation centers. <i>World Journal of Urology</i> , 2019, 37, 957-967.	2.2	7
98	Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1000-1008.	0.7	31
99	Validation of the Living Kidney Donor Profile Index in a European cohort and comparison of long-term outcomes with US results. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1063-1070.	0.7	23
100	Risks and benefits of everolimus. <i>Transplant International</i> , 2019, 32, 1124-1126.	1.6	0
101	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. <i>Frontiers in Neurology</i> , 2019, 10, 821.	2.4	18
102	Analysis of the Effects of Day-Time vs. Night-Time Surgery on Renal Transplant Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1051.	2.4	16
103	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. <i>Frontiers in Neurology</i> , 2019, 10, 705.	2.4	22
104	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1056-1066.	4.5	49
105	Native Nephrectomy before and after Renal Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). <i>Journal of Clinical Medicine</i> , 2019, 8, 1622.	2.4	11
106	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. <i>Frontiers in Neurology</i> , 2019, 10, 1144.	2.4	11
107	Pregnancy following kidney transplantation - impact on mother and graft function and focus on childrens™ longitudinal development. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 376.	2.4	28
108	Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1605-1611.	0.7	12



#	ARTICLE	IF	CITATIONS
109	Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). PLoS ONE, 2019, 14, e0222730.	2.5	7
110	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 2078-2081.	27.0	20
111	Pre-existing malignancies in renal transplant candidates—time to reconsider waiting times. Nephrology Dialysis Transplantation, 2019, 34, 1292-1300.	0.7	15
112	First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS ONE, 2019, 14, e0212023.	2.5	41
113	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	13.7	408
114	A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. BMC Nephrology, 2019, 20, 36.	1.8	7
115	TBC1D8B Mutations Implicate RAB11-Dependent Vesicular Trafficking in the Pathogenesis of Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2338-2353.	6.1	25
116	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus—Positive Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 53-58.	2.0	3
117	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
118	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials, 2019, 20, 37.	1.6	48
119	Epilepsy in tuberous sclerosis complex: Findings from the <sc>TOSCA</sc> Study. Epilepsia Open, 2019, 4, 73-84.	2.4	125
120	Effectiveness and Harms of Using Kidneys with Small Renal Tumors from Deceased or Living Donors as a Source of Renal Transplantation: A Systematic Review. European Urology Focus, 2019, 5, 508-517.	3.1	14
121	Late Steroid Withdrawal Following ABO-Incompatible Renal Transplantation. Transplantation Proceedings, 2018, 50, 72-78.	0.6	1
122	Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized <sc>EXIST</sc>#1 and <sc>EXIST</sc>#2 studies. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1796-1803.	2.4	26
123	Assessment of the Kidney Donor Profile Index in a European cohort. Nephrology Dialysis Transplantation, 2018, 33, 1465-1472.	0.7	36
124	Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients. American Journal of Transplantation, 2018, 18, 1810-1814.	4.7	34
125	Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. American Journal of Transplantation, 2018, 18, 1726-1734.	4.7	47
126	High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation. CKJ: Clinical Kidney Journal, 2018, 11, 564-573.	2.9	13



#	ARTICLE	IF	CITATIONS
127	Recent advances in kidney transplantation: a viewpoint from the Descartes advisory board*. Nephrology Dialysis Transplantation, 2018, 33, 1699-1707.	0.7	42
128	Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex. Scientific Reports, 2018, 8, 953.	3.3	13
129	Any Progress in the Treatment of Antibody-Mediated Rejection?. Journal of the American Society of Nephrology: JASN, 2018, 29, 350-352.	6.1	22
130	European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care. Nephrology Dialysis Transplantation, 2018, 33, 563-573.	0.7	28
131	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	4.7	11
132	Investigation of the physical and psychosocial outcomes after living kidney donation - a multicenter cohort study (SoLKID - Safety of Living Kidney Donors). BMC Nephrology, 2018, 19, 83.	1.8	9
133	Conversion to Belatacept in Maintenance Kidney Transplant Patients. Transplantation, 2018, 102, 1545-1552.	1.0	43
134	Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf <sup>®</sup> , <sup>®</sup> ) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clinical Transplantation, 2018, 32, e13142.	1.6	18
135	Invited letter in response to "Predicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg". American Journal of Transplantation, 2018, 18, 523-524.	4.7	2
136	High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation. Journal of Women's Health, 2018, 27, 394-398.	3.3	6
137	Adjustment of target weight based on absolute blood volume reduces the frequency of intradialytic morbid events. Hemodialysis International, 2018, 22, 254-260.	0.9	19
138	The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review. European Urology, 2018, 73, 94-108.	1.9	46
139	Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial. Transplantation Direct, 2018, 4, e380.	1.6	19
140	Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 3232-3241.	0.6	14
141	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrology, 2018, 19, 237.	1.8	14
142	The regulation of interferon type I pathway-related genes RSAD2 and ETV7 specifically indicates antibody-mediated rejection after kidney transplantation. Clinical Transplantation, 2018, 32, e13429.	1.6	14
143	USE OF A MOBILE APP TO IMPROVE MEDICATION ADHERENCE IN KIDNEY TRANSPLANT RECIPIENTS - A PROSPECTIVE INTERVENTIONAL STUDY. Nephrology Dialysis Transplantation, 2018, 33, i321-i321.	0.7	1
144	Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis. PLoS ONE, 2018, 13, e0201005.	2.5	27

#	ARTICLE	IF	CITATIONS
145	Psychosocial Long-Term Impact of Donation on Kidney Living Donors - A Comparative Study of Two Major European Transplant Centres. <i>Transplantation</i> , 2018, 102, S612.	1.0	0
146	Range and Consistency of Outcomes Reported in Randomized Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2018, 102, 2065-2071.	1.0	26
147	FP713DE NOVO MALIGNANCIES AFTER KIDNEY TRANSPLANTATION: A LONG-TERM OBSERVATIONAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i286-i286.	0.7	0
148	European Association of Urology Guidelines on Renal Transplantation: Update 2018. <i>European Urology Focus</i> , 2018, 4, 208-215.	3.1	85
149	A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. <i>American Journal of Transplantation</i> , 2018, 18, 2945-2954.	4.7	46
150	MicroRNA regulation in blood cells of renal transplanted patients with interstitial fibrosis/tubular atrophy and antibody-mediated rejection. <i>PLoS ONE</i> , 2018, 13, e0201925.	2.5	20
151	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , 2018, 19, 154.	1.8	3
152	Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13311.	1.6	12
153	Prophylaxis and treatment of <i>Pneumocystis Jirovecii</i> pneumonia after solid organ transplantation. <i>Pharmacological Research</i> , 2018, 134, 61-67.	7.1	33
154	A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation. <i>PLoS ONE</i> , 2018, 13, e0193569.	2.5	11
155	Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw368.	0.7	34
156	Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation. <i>Transplantation</i> , 2017, 101, 2165-2174.	1.0	32
157	Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection. <i>Transplantation</i> , 2017, 101, 2017-2025.	1.0	8
158	Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 3076-3086.	4.7	117
159	Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide. <i>Transplantation</i> , 2017, 101, 2545-2552.	1.0	14
160	Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation. <i>Critical Care Medicine</i> , 2017, 45, e941-e946.	0.9	45
161	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1060-1070.	0.7	31
162	Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 880-889.	0.7	15

#	ARTICLE	IF	CITATIONS
163	Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 216-223.	0.7	79
164	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2017, 92, 796-808.	5.2	40
165	Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. <i>Transplantation Proceedings</i> , 2017, 49, 1747-1756.e1.	0.6	15
166	Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome. <i>Transplantation Proceedings</i> , 2017, 49, 1757-1765.	0.6	14
167	Urinary miR-155 and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2636-2650.	2.4	49
168	Transplanting HCV-Infected Kidneys into Uninfected Recipients. <i>New England Journal of Medicine</i> , 2017, 377, 1103-1105.	27.0	29
169	Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1887-1896.	1.0	83
170	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1875-1886.	1.0	68
171	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. <i>Transplantation Proceedings</i> , 2017, 49, 2269-2273.	0.6	10
172	Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis. <i>Transplantation Proceedings</i> , 2017, 49, 2256-2259.	0.6	9
173	Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. <i>Transplantation Proceedings</i> , 2017, 49, 2280-2284.	0.6	6
174	Immunologic Long-term Outcomes of Living-Related Kidney Transplantations Depending on the Donor-Recipient Relationship. <i>Transplantation Proceedings</i> , 2017, 49, 2265-2268.	0.6	1
175	A novel tool for the identification of correlations in medical data by faceted search. <i>Computers in Biology and Medicine</i> , 2017, 85, 98-105.	7.0	9
176	Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients. <i>Transplantation</i> , 2017, 101, 2780-2788.	1.0	13
177	Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus-Associated Membranoproliferative Glomerulonephritis. <i>American Journal of Transplantation</i> , 2017, 17, 819-823.	4.7	5
178	Biomarkers in acute kidney injury – pathophysiological basis and clinical performance. <i>Acta Physiologica</i> , 2017, 219, 556-574.	3.8	238
179	Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. <i>Pediatric Nephrology</i> , 2017, 32, 1137-1144.	1.7	27
180	Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	2.2	10

#	ARTICLE	IF	CITATIONS
181	Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. <i>PLoS ONE</i> , 2017, 12, e0180939.	2.5	128
182	Development of Graft-Site Candidiasis in 3 Solid Organ Transplant Recipients from the Same Donor. <i>American Journal of Case Reports</i> , 2017, 18, 777-781.	0.8	5
183	Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC). <i>PLoS ONE</i> , 2017, 12, e0189132.	2.5	12
184	FrÃ¼he Umstellung von Cyclosporin auf Everolimus nach Lebendnierentransplantation: 5 Jahresdaten der randomisierten ZEUS Studie. <i>Nieren- Und Hochdruckkrankheiten</i> , 2017, 46, 105-117.	0.0	0
185	mHealth und digitales Management nach Nierentransplantation. <i>Nieren- Und Hochdruckkrankheiten</i> , 2017, 46, 474-480.	0.0	1
186	Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation. <i>Transplantation Direct</i> , 2016, 2, e79.	1.6	30
187	The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop <i>de novo</i> thrombotic microangiopathy. <i>Clinical Transplantation</i> , 2016, 30, 105-117.	1.6	22
188	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20.	2.0	78
189	Identification of T Cell-Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood. <i>Transplantation</i> , 2016, 100, 898-907.	1.0	32
190	Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2143-2149.	0.7	21
191	Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S43-S49.	2.0	6
192	Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangiomyomatosis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 958-970.	2.4	23
193	Improved Left Ventricular Structure and Function After Successful Kidney Transplantation. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 701-709.	2.0	41
194	Risk Evaluation and Outcome of <i>Pneumocystis jirovecii</i> Pneumonia in Kidney Transplant Patients. <i>Transplantation Proceedings</i> , 2016, 48, 2924-2930.	0.6	23
195	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	2.0	102
196	Immunosuppression in the elderly renal allograft recipient: a systematic review. <i>Transplantation Reviews</i> , 2016, 30, 144-153.	2.9	25
197	PD04-03 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TSC OR SLAM: FINAL LONG-TERM RESULTS FROM EXIST-2. <i>Journal of Urology</i> , 2016, 195, .	0.4	3
198	The Clinical Data Intelligence Project. <i>Informatik-Spektrum</i> , 2016, 39, 290-300.	1.3	14

#	ARTICLE	IF	CITATIONS
199	Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1351-1359.	0.7	26
200	"I feel stronger and younger all the time" perspectives of elderly kidney transplant recipients: thematic synthesis of qualitative research. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1531-1540.	0.7	25
201	Review of the Tuberos Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. <i>Nephron</i> , 2016, 134, 51-58.	1.8	58
202	Free microRNA levels in plasma distinguish T-cell mediated rejection from stable graft function after kidney transplantation. <i>Transplant Immunology</i> , 2016, 39, 52-59.	1.2	17
203	Effect of everolimus on skin lesions in patients being treated for subependymal giant cell astrocytoma and renal angiomyolipoma: Final 4-year results from EXIST-1 and EXIST-2. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, AB127.	1.2	0
204	The selective biomarker IL-8 identifies IFTA after kidney transplantation in blood cells. <i>Transplant Immunology</i> , 2016, 39, 18-24.	1.2	6
205	Once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. <i>Transplant International</i> , 2016, 29, 603-611.	1.6	25
206	Immunosuppression and Results in Renal Transplantation. <i>European Urology Supplements</i> , 2016, 15, 415-429.	0.1	9
207	Experience with belatacept rescue therapy in kidney transplant recipients. <i>Transplant International</i> , 2016, 29, 1184-1195.	1.6	46
208	Clinical outcome of norovirus infection in renal transplant patients. <i>Clinical Transplantation</i> , 2016, 30, 1283-1293.	1.6	10
209	Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 612-619.	1.2	5
210	Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. <i>Transplantation Direct</i> , 2016, 2, e91.	1.6	16
211	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 648-659.	1.9	78
212	The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1002-1013.	0.7	46
213	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 691-697.	0.7	62
214	Motivations, Challenges, and Attitudes to Self-management in Kidney Transplant Recipients: A Systematic Review of Qualitative Studies. <i>American Journal of Kidney Diseases</i> , 2016, 67, 461-478.	1.9	116
215	Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: extension of a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 111-119.	0.7	120
216	Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. <i>Journal of Clinical Investigation</i> , 2016, 126, 2519-2532.	8.2	181

#	ARTICLE	IF	CITATIONS
217	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. <i>Clinical Nephrology</i> , 2016, 85 (2016), 215-225.	0.7	9
218	Nierenfunktion, Wirksamkeit und Sicherheit nach später Umstellung von Calcineurininhibitoren auf Everolimus bei Patienten nach Nierentransplantation: die randomisierte APOLLO-Studie. <i>Nieren- Und Hochdruckkrankheiten</i> , 2016, 45, 145-156.	0.0	0
219	PD35-10 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EFFICACY AND SAFETY AFTER 3.5 YEARS OF TREATMENT IN THE EXIST-2 STUDY. <i>Journal of Urology</i> , 2015, 193, .	0.4	2
220	Current status of immunosuppressive minimization and tolerance strategies. <i>Transplant International</i> , 2015, 28, 889-890.	1.6	4
221	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1086-1096.	2.4	16
222	Renal Allograft Loss Caused by Cardiorenal Syndrome. <i>Transplantation</i> , 2015, 99, 1208-1215.	1.0	8
223	The Relationship of the Severity and Category of Acute Rejection With Intimal Arteritis Defined in Banff Classification to Clinical Outcomes. <i>Transplantation</i> , 2015, 99, e105-e114.	1.0	12
224	“Suspended in a paradox”-patient attitudes to wait-listing for kidney transplantation: systematic review and thematic synthesis of qualitative studies. <i>Transplant International</i> , 2015, 28, 771-787.	1.6	44
225	FP825IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii352-iii353.	0.7	0
226	FP834IMPACT OF PREGNANCIES ON IMMUNIZATION AND OUTCOME IN KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii356-iii356.	0.7	0
227	FP837BODY MASS INDEX (BMI) MISMATCH IN DECEASED KIDNEY DONATION IS AN INDEPENDENT RISK FACTOR FOR GRAFT FAILURE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii357-iii357.	0.7	0
228	FP870HLA-DR MATCHING IMPROVES IMMUNOLOGIC OUTCOMES IN ELDERLY KIDNEY TRANSPLANT RECIPIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii367-iii368.	0.7	0
229	Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients. <i>American Journal of Transplantation</i> , 2015, 15, 1644-1653.	4.7	50
230	Strategies to increase the donor pool and access to kidney transplantation: an international perspective. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 217-222.	0.7	68
231	Renal transplantation in the elderly. <i>Transplantation Reviews</i> , 2015, 29, 191-192.	2.9	7
232	Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte $\beta$ 3-integrin Activation. <i>Transplantation</i> , 2015, 99, 2593-2597.	1.0	38
233	Living Donor Transplantation: Long-Term Evolution Related to Age Matching. <i>Transplantation Proceedings</i> , 2015, 47, 2346-2350.	0.6	2
234	Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study. <i>American Journal of Transplantation</i> , 2015, 15, 119-128.	4.7	109



#	ARTICLE	IF	CITATIONS
235	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. <i>Clinical Nephrology</i> , 2015, 83 (2015), 11-21.	0.7	33
236	Midterm echocardiographic follow-up of cardiac function after living kidney donation. <i>Clinical Nephrology</i> , 2015, 83 (2015), 253-261.	0.7	7
237	Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2015, 31, gfv077.	0.7	9
238	Bortezomib-Based Antibody Reduction Therapy: The First Step to "True" Desensitization?. <i>American Journal of Transplantation</i> , 2015, 15, 10-12.	4.7	5
239	Advances in pharmacotherapy to treat kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1627-1648.	1.8	9
240	The need for minimization strategies: current problems of immunosuppression. <i>Transplant International</i> , 2015, 28, 891-900.	1.6	104
241	Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease. <i>Clinical and Experimental Nephrology</i> , 2015, 19, 757-758.	1.6	0
242	Clinical and Molecular Characterization of Patients with Heterozygous Mutations in Wilms Tumor Suppressor Gene 1. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 825-831.	4.5	52
243	Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. <i>Journal of Nephrology</i> , 2015, 28, 115-123.	2.0	16
244	Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. <i>Transplant International</i> , 2015, 28, 710-719.	1.6	30
245	Need for optimized immunosuppression in elderly kidney transplant recipients. <i>Transplantation Reviews</i> , 2015, 29, 237-239.	2.9	33
246	Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation. <i>Transplant Immunology</i> , 2015, 33, 176-184.	1.2	3
247	Echokardiografische Evaluation von Veränderungen der kardialen Struktur und Funktion nach Lebendnierenspende. <i>Nieren- Und Hochdruckkrankheiten</i> , 2015, 44, 501-510.	0.0	0
248	Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study. <i>Journal of Transplantation</i> , 2014, 2014, 1-10.	0.5	8
249	Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: Follow-Up of the HERAKLES Study at Month 36.. <i>Transplantation</i> , 2014, 98, 81.	1.0	4
250	Conversion From Tacrolimus to Cyclosporine A Improves Glucose Metabolism in Patients With New Onset Diabetes After Transplantation: Interim Analysis of a Prospective and Randomized Study.. <i>Transplantation</i> , 2014, 98, 95.	1.0	2
251	Efficacy and Safety of Three Different Treatment Regimens in De Novo Renal Transplant Patients: Month 36 Follow-Up Results of HERAKLES Trial.. <i>Transplantation</i> , 2014, 98, 81-82.	1.0	3
252	Once-Daily Envarsus Demonstrates Comparable Efficacy and Safety to Twice-Daily Prograf: A Phase 3 Study for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients.. <i>Transplantation</i> , 2014, 98, 116.	1.0	0



#	ARTICLE	IF	CITATIONS
253	Two-Year Results of Envarsus (Once-Daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-Daily) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Study.. Transplantation, 2014, 98, 661-662.	1.0	1
254	Rapid Attainment of Tacrolimus Trough Levels Early Post-Transplant Reduces Risk of Treatment Failure in De Novo Kidney Transplant Patients: A Covariate Analysis of a Phase 3 Double-Blind Study.. Transplantation, 2014, 98, 459.	1.0	0
255	Post Hoc Analysis of ZEUS and HERAKLES, Two Prospective, Open-Label, Multicenter, Randomized Trials: Onset and Progression of Diabetes in Kidney Transplant Recipients On Cyclosporine Standard or Converted to CNI-Free or CNI-Low Everolimus Regimen.. Transplantation, 2014, 98, 145-146.	1.0	1
256	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	11
257	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	5.2	91
258	Clindamycin+primaquine for pneumocystis jiroveci pneumonia in renal transplant patients. Infection, 2014, 42, 981-989.	4.7	18
259	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opinion on Drug Safety, 2014, 13, 361-372.	2.4	30
260	Genetic polymorphisms in <i>IL2</i> , <i>IL10</i> , <i>TGF-<math>\beta</math>1</i> , and <i>IL2</i> <i>RB</i> and acute rejection in renal transplant patients. Clinical Transplantation, 2014, 28, 649-655.	1.6	19
261	Complement-Binding Anti-HLA Antibodies and Kidney Transplantation. New England Journal of Medicine, 2014, 370, 83-86.	27.0	12
262	Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. Clinical Transplantation, 2014, 28, 410-418.	1.6	17
263	The efficacy and safety of cyclosporine reduction in <i>de novo</i> renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. Transplant International, 2014, 27, 176-186.	1.6	10
264	Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transplant International, 2014, 27, 77-86.	1.6	125
265	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	180
266	Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation. Antioxidants and Redox Signaling, 2014, 21, 2401-2418.	5.4	45
267	Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database. Clinical Transplantation, 2014, 28, 67-79.	1.6	13
268	Human Leukocyte Antigen "Incompatible Kidney Transplantation After "Desensitization" Hope and Reality. Transplantation, 2014, 98, 819-820.	1.0	4
269	The Severity of Acute Cellular Rejection Defined by Banff Classification Is Associated With Kidney Allograft Outcomes. Transplantation, 2014, 97, 1146-1154.	1.0	54
270	The Preferences and Perspectives of Nephrologists on Patients' Access to Kidney Transplantation. Transplantation, 2014, 98, 682-691.	1.0	39

#	ARTICLE	IF	CITATIONS
271	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 71-79.	2.0	81
272	Fate of Finally Transplanted Deceased Donor Kidneys Initially Rejected at Other Kidney Transplantation Centers. <i>Urologia Internationalis</i> , 2014, 93, 474-481.	1.3	5
273	Novel Once-Daily Extended-Release Tacrolimus (LCPT) Versus Twice-Daily Tacrolimus in De Novo Kidney Transplants: One-Year Results of Phase III, Double-Blind, Randomized Trial. <i>American Journal of Transplantation</i> , 2014, 14, 2796-2806.	4.7	96
274	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. <i>Transplant International</i> , 2014, 27, 1192-1204.	1.6	6
275	PD17-01 EVEROLIMUS FOR RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX: EXIST-2 LONG-TERM EFFICACY AND SAFETY. <i>Journal of Urology</i> , 2014, 191, .	0.4	1
276	Intensivierte vs. standardmäßige Dosierung von magensaftresistentem Mycophenolat- Natrium bei De-novo-Nierentransplantatempfängern: 1-Jahres-Ergebnisse einer randomisierten Studie. <i>Nieren- Und Hochdruckkrankheiten</i> , 2014, 43, 297-309.	0.0	0
277	Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution. <i>World Journal of Urology</i> , 2013, 31, 947-952.	2.2	8
278	Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: computed tomography angiography versus magnetic resonance angiography in 118 patients. <i>World Journal of Urology</i> , 2013, 31, 983-990.	2.2	23
279	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	2.1	1,185
280	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	2.1	693
281	Effect of everolimus, an oral mtor inhibitor, on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC) and skin lesions. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, AB48.	1.2	0
282	Combined standard and novel immunosuppressive substances affect B-lymphocyte function. <i>International Immunopharmacology</i> , 2013, 15, 718-725.	3.8	12
283	Novel views on new-onset diabetes after transplantation: development, prevention and treatment. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 550-566.	0.7	100
284	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 817-824.	13.7	712
285	New Perspectives of Immunosuppression. <i>Transplantation Proceedings</i> , 2013, 45, 1224-1231.	0.6	10
286	Volume matters: CT-based renal cortex volume measurement in the evaluation of living kidney donors. <i>Transplant International</i> , 2013, 26, 1208-1216.	1.6	42
287	Frequency and long-term outcomes of post-transplant hypophosphatemia after kidney transplantation. <i>Transplant International</i> , 2013, 26, e94-e96.	1.6	9
288	Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results. <i>American Journal of Transplantation</i> , 2013, 13, 1746-1756.	4.7	38

#	ARTICLE	IF	CITATIONS
289	Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1757-1768.	4.7	34
290	Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. <i>Acta Physiologica</i> , 2013, 207, 663-672.	3.8	206
291	Belatacept utilization recommendations: an expert position. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 111-122.	2.4	12
292	Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial. <i>American Journal of Transplantation</i> , 2013, 13, 760-769.	4.7	82
293	Treatment With Sirolimus Is Associated With Less Weight Gain After Kidney Transplantation. <i>Transplantation</i> , 2013, 96, 480-486.	1.0	8
294	A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. <i>Clinical Nephrology</i> , 2013, 79, 421-431.	0.7	7
295	Post-Transplantations-Diabetes mellitus nach Nierentransplantation. <i>Nieren- Und Hochdruckkrankheiten</i> , 2013, 42, 532-538.	0.0	0
296	Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1246-1251.	0.7	108
297	An evaluation of sirolimus in renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1337-1356.	3.3	26
298	Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix(R)) in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 423-428.	0.7	69
299	Sirolimus for secondary SCC prevention in renal transplantation. <i>Nature Reviews Nephrology</i> , 2012, 8, 687-689.	9.6	10
300	A Cardiovascular Risk Calculator for Renal Transplant Recipients. <i>Transplantation</i> , 2012, 94, 57-62.	1.0	56
301	Pretransplant PRA and Long-Term Outcomes of Kidney Transplant Recipients. <i>Transplantation</i> , 2012, 94, 1076.	1.0	0
302	About Incidence and Timing of Donor-Specific Antibodies After Graft Nephrectomy. <i>Transplantation</i> , 2012, 93, 865-866.	1.0	3
303	Clindamycin-Primaquine Is Safe in Treating Pneumocystis Pneumonia in Renal Transplant Patients but Appears to Be Less Effective than Trimethoprim/Sulfamethoxazole. <i>Transplantation</i> , 2012, 94, 547.	1.0	0
304	The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 241.	1.0	0
305	Determinants of Outcome after KTX in Elderly Patients. <i>Transplantation</i> , 2012, 94, 922.	1.0	0
306	Superior Renal Function in an Everolimus-Based Calcineurin Inhibitor Free Regimen Compared to Standard Cyclosporine/Mycophenolate and Low Cyclosporine/Everolimus: The HERAKLES Study. <i>Transplantation</i> , 2012, 94, 993.	1.0	1

#	ARTICLE	IF	CITATIONS
307	The Effect of Acute Rejection Episodes According to Banff 2009 on Long-Term Outcome of Patients after Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 1044.	1.0	0
308	Determinants and Duration of Hospitalisations after KTX in Elderly Patients. <i>Transplantation</i> , 2012, 94, 918.	1.0	0
309	Improved Renal Function of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in de Novo Renal Transplant Patients: 4 Years Follow-Up of the ZEUS Trial. <i>Transplantation</i> , 2012, 94, 993.	1.0	1
310	Renal Function of an Everolimus Based Therapy after Calcineurin Inhibitor Withdrawal in Maintenance Renal Transplant Recipients: 3 Year Data of the APOLLO Trial. <i>Transplantation</i> , 2012, 94, 994.	1.0	1
311	A Phase III Randomized Trial of Conversion to Once-Daily Extended Release Meltedose <sup>®</sup> Tacrolimus Tablets (LCP-Tacro <sup>®</sup> , <sup>®</sup> ) from Twice-Daily Tacrolimus Capsules (Prograf <sup>®</sup> ): Efficacy Results from an Analysis of Specific Patient Sub-Populations. <i>Transplantation</i> , 2012, 94, 984.	1.0	0
312	Effects of Sotrastaurin, Mycophenolic Acid and Everolimus on Human B-Lymphocyte Function and Activation. <i>Transplantation</i> , 2012, 94, 1117.	1.0	0
313	Pre-Operative Assessment of Living Renal Transplant Donors with State-Of-The-Art Imaging Modalities: Computed Tomography Angiography vs. Magnetic Resonance Angiography in 118 Patients. <i>Transplantation</i> , 2012, 94, 187.	1.0	0
314	Sotrastaurin + Reduced-Exposure Tacrolimus Prevents Acute Rejection and Preserves Renal Function after De Novo Kidney Transplantation - 12 Month Results. <i>Transplantation</i> , 2012, 94, 980.	1.0	1
315	Efficacy and Safety of Three Different Treatment Regimens in de Novo Renal Transplant Patients: Results of the HERAKLES Trial. <i>Transplantation</i> , 2012, 94, 995.	1.0	3
316	Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT). <i>Transplantation</i> , 2012, 94, 996.	1.0	1
317	IMP-Dehydrogenase in Erythrocytes for Detection of Non-Adherence to MPA Therapy. <i>Transplantation</i> , 2012, 94, 1191.	1.0	0
318	Immunosuppressive Potential and Side Effects of Everolimus. <i>American Journal of Transplantation</i> , 2012, 12, 2563-2563.	4.7	2
319	Mycophenolate mofetil maintenance therapy in renal transplant patients: long-term results of the T <sup>ran</sup> C <sup>ept</sup> STAY study. <i>Clinical Transplantation</i> , 2012, 26, 919-926.	1.6	9
320	Non-invasive imaging of living kidney donors: intraindividual comparison of multislice computed tomography angiography with magnetic resonance angiography. <i>Clinical Transplantation</i> , 2012, 26, E412-7.	1.6	14
321	Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year. <i>American Journal of Transplantation</i> , 2012, 12, 2446-2456.	4.7	140
322	1302 EXIST-2: EFFECT OF EVEROLIMUS ON ANGIOMYOLIPOMA IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX OR SPORADIC LYMPHANGIOMYOMATOSIS. <i>Journal of Urology</i> , 2012, 187, .	0.4	1
323	Inosine 5 <sup>α</sup> -monophosphate dehydrogenase activity as a biomarker in the field of transplantation. <i>Clinica Chimica Acta</i> , 2012, 413, 1391-1397.	1.1	25
324	Identification and Therapeutic Management of Highly Sensitized Patients Undergoing Renal Transplantation. <i>Drugs</i> , 2012, 72, 1335-1354.	10.9	27

#	ARTICLE	IF	CITATIONS
325	Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. <i>Transplantation Reviews</i> , 2012, 26, 233-240.	2.9	17
326	Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 913-922.	1.9	18
327	Tuberous Sclerosis Complex-associated Angiomyolipomas: Focus on mTOR Inhibition. <i>American Journal of Kidney Diseases</i> , 2012, 59, 276-283.	1.9	91
328	Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 1192-1198.	4.7	231
329	Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplant: 3-Year Results From the Randomized ZEUS Study. <i>American Journal of Transplantation</i> , 2012, 12, 1528-1540.	4.7	77
330	Weight gain in long-term survivors of kidney or liver transplantation—Another paradigm of sarcopenic obesity?. <i>Nutrition</i> , 2012, 28, 378-383.	2.4	71
331	Tacrolimus only for breakfast —*. <i>Transplant International</i> , 2012, 25, 274-275.	1.6	2
332	Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation. <i>Transplant International</i> , 2012, 25, 1106-1116.	1.6	32
333	Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2. <i>Journal of Clinical Oncology</i> , 2012, 30, 356-356.	1.6	5
334	Diets and enteral supplements for improving outcomes in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 369-384.	9.6	147
335	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	3.5	170
336	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. <i>Lancet</i> , 2011, 377, 837-847.	13.7	326
337	Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. <i>Transplantation</i> , 2011, 91, 779-785.	1.0	26
338	Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients. <i>Transplantation</i> , 2011, 92, 321-327.	1.0	11
339	Pharmacokinetics of Sotrastaurin Combined With Tacrolimus or Mycophenolic Acid in De Novo Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 91, 317-322.	1.0	17
340	Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 179-184.	1.5	43
341	Biomarkers of Over-Immunosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 316-322.	4.7	31
342	Accumulation of elderly ESRD patients with blood group O on the waiting list. <i>Transplant International</i> , 2011, 24, e83-e84.	1.6	8

#	ARTICLE	IF	CITATIONS
343	Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome. <i>Annals of Human Genetics</i> , 2011, 75, 639-647.	0.8	29
344	Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 1444-1455.	4.7	75
345	How to Use mTOR Inhibitors? The Search Goes On. <i>American Journal of Transplantation</i> , 2011, 11, 1551-1552.	4.7	7
346	Reduction of Gastrointestinal Complications in Renal Graft Recipients after Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium. <i>Transplantation Proceedings</i> , 2011, 43, 1641-1646.	0.6	15
347	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. <i>Transplantation Reviews</i> , 2011, 25, 58-64.	2.9	65
348	Desensitization of HLA-Incompatible Kidney Recipients. <i>New England Journal of Medicine</i> , 2011, 365, 1643-1645.	27.0	8
349	Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 103-113.	3.3	28
350	How Delayed Graft Function Impacts Exposure to Mycophenolic Acid in Patients After Renal Transplantation. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 155-164.	2.0	17
351	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 560-572.	2.0	54
352	RENAL FUNCTION OF AN EVEROLIMUS BASED THERAPY AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS ONE YEAR AFTER CONVERSION. <i>Transplantation</i> , 2010, 90, 612.	1.0	0
353	Target Enzyme Activity as a Biomarker for Immunosuppression. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 257-260.	2.0	6
354	Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. <i>Transplantation</i> , 2010, 89, 595-599.	1.0	48
355	Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal-Transplant Recipients. <i>American Journal of Transplantation</i> , 2010, 10, 571-581.	4.7	78
356	Epidemiological Approach to Identifying Genetic Predispositions for Atypical Hemolytic Uremic Syndrome. <i>Annals of Human Genetics</i> , 2010, 74, 17-26.	0.8	60
357	Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 346-357.	2.4	57
358	Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. <i>Transplant International</i> , 2010, 23, 1191-1204.	1.6	98
359	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 503-511.	4.5	40
360	The 'blood group O problem' in kidney transplantation--time to change?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1998-2004.	0.7	42



#	ARTICLE	IF	CITATIONS
361	Effects of the new immunosuppressive agent AEB071 on human immune cells. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2159-2167.	0.7	18
362	Increased Incidence of Angioedema with ACE Inhibitors in Combination with mTOR Inhibitors in Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 703-708.	4.5	74
363	Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 283-292.	0.7	7
364	IMPROVED RENAL FUNCTION OF AN EVEROLIMUS/ENTERIC-COATED MYCOPHENOLATE SODIUM REGIMEN AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN DE NOVO RENAL TRANSPLANT PATIENTS: 2 YEARS FOLLOW-UP OF THE ZEUS TRIAL. <i>Transplantation</i> , 2010, 90, 109.	1.0	6
365	De novo Renal Transplantation after Kaposi Sarcoma: Favorable Outcome in a Patient Receiving Sirolimus and Mycophenolate-Based Immunosuppression. <i>Case Reports in Dermatology</i> , 2010, 2, 32-35.	0.8	3
366	Comparison of first and second kidney transplants from the same deceased donor. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 4055-4061.	0.7	19
367	AN INTENSIFIED DOSING OF ENTERIC-COATED MYCOPHENOLATE SODIUM IN RENAL TRANSPLANT PATIENTS RESULTS IN IMPROVED EFFICACY WITHOUT COMPROMISING SAFETY: 1 YEAR FOLLOW-UP RESULTS. <i>Transplantation</i> , 2010, 90, 611.	1.0	0
368	Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 2010, 363, 830-840.	27.0	517
369	Superior Efficacy of Enteric-coated Mycophenolate vs Mycophenolate Mofetil in De Novo Transplant Recipients: Pooled Analysis. <i>Transplantation Proceedings</i> , 2010, 42, 1325-1328.	0.6	10
370	Why Rejections Are Not Biopsy Proven: Frequency and Reasons. <i>Transplantation Proceedings</i> , 2010, 42, 4509-4512.	0.6	4
371	Enteric-coated mycophenolate sodium. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 981-994.	2.4	40
372	Outcomes of Transplanting Deceased-Donor Kidneys between Elderly Donors and Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 37-40.	6.1	47
373	The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F218-F227.	2.7	16
374	Pharmacodynamic Evaluation of the First Dose of Mycophenolate Mofetil Before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 936-942.	4.5	24
375	Treatment of PTLD with Rituximab and CHOP Reduces the Risk of Renal Graft Impairment after Reduction of Immunosuppression. <i>American Journal of Transplantation</i> , 2009, 9, 2331-2337.	4.7	42
376	UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 319-327.	4.7	112
377	Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 218-223.	2.0	19
378	Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts. <i>Transplantation</i> , 2009, 87, 1505-1513.	1.0	313



#	ARTICLE	IF	CITATIONS
379	A Randomized Trial Comparing Renal Function in Older Kidney Transplant Patients Following Delayed Versus Immediate Tacrolimus Administration. <i>Transplantation</i> , 2009, 88, 1101-1108.	1.0	45
380	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 626-634.	1.5	71
381	Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 351-359.	2.0	51
382	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 585-591.	2.0	27
383	Attitude to nephrolithiasis in the potential living kidney donor: a survey of the German kidney transplant centers and review of the literature. <i>Clinical Transplantation</i> , 2008, 22, 476-483.	1.6	13
384	Cross-over Kidney Transplantation with Simultaneous Laparoscopic Living Donor Nephrectomy: Initial Experience. <i>European Urology</i> , 2008, 53, 1074-1078.	1.9	5
385	Immunosuppression in renal transplantation: some aspects for the modern era. <i>Transplantation Reviews</i> , 2008, 22, 241-251.	2.9	19
386	Population Pharmacokinetics of Mycophenolic Acid. <i>Clinical Pharmacokinetics</i> , 2008, 47, 827-838.	3.5	79
387	<i>Tabebuia avellanedae</i> extracts inhibit IL-2-independent T-lymphocyte activation and proliferation. <i>Transplant Immunology</i> , 2008, 18, 319-323.	1.2	17
388	Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. <i>Cytokine</i> , 2008, 42, 306-311.	3.2	11
389	Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F440-F449.	2.7	58
390	Arrival Time Parametric Imaging: A New Ultrasound Technique for Quantifying Perfusion of Kidney Grafts. <i>Ultraschall in Der Medizin</i> , 2008, 29, 418-423.	1.5	27
391	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. <i>Transplantation</i> , 2008, 86, 1043-1051.	1.0	238
392	AcylIMPAG Plasma Concentrations and Mycophenolic Acid-Related Side Effects in Patients Undergoing Renal Transplantation Are Not Related to the UGT2B7-840C>A Gene Polymorphism. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 439-444.	2.0	40
393	CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 339-348.	1.5	110
394	Aktuelle Aspekte der Immunsuppression nach Nierentransplantation. <i>Nieren- Und Hochdruckkrankheiten</i> , 2008, 37, 602-613.	0.0	0
395	Pharmacokinetic principles of immunosuppressive drugs. <i>Annals of Transplantation</i> , 2008, 13, 5-10.	0.9	2
396	S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F1761-F1770.	2.7	23

#	ARTICLE	IF	CITATIONS
397	The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2354-2358.	0.7	16
398	Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 850-859.	2.0	22
399	Pregnancy on Intensified Hemodialysis: Fetal Surveillance and Perinatal Outcome. <i>Fetal Diagnosis and Therapy</i> , 2007, 22, 289-293.	1.4	32
400	Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Maintenance Renal Transplant Recipients Receiving Tacrolimus: Clinical, Pharmacokinetic, and Pharmacodynamic Outcomes. <i>Transplantation</i> , 2007, 83, 417-424.	1.0	71
401	Validation of Immunological Biomarkers for the Pharmacodynamic Monitoring of Immunosuppressive Drugs in Humans. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 77-86.	2.0	60
402	Enteric-Coated Mycophenolate Sodium Provides Higher Mycophenolic Acid Predose Levels Compared With Mycophenolate Mofetil: Implications for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 381-384.	2.0	34
403	Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies. <i>Transplantation Proceedings</i> , 2007, 39, 1386-1391.	0.6	20
404	Differential effects of single dose FTY720 on CD62L+ B-cells in stable renal allograft recipients. <i>International Immunopharmacology</i> , 2007, 7, 88-95.	3.8	7
405	Current perspectives on FTY720. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 505-518.	4.1	19
406	Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. <i>Transplant International</i> , 2007, 21, 071115125226003-???	1.6	27
407	Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. <i>Clinical Transplantation</i> , 2007, 21, 117-125.	1.6	15
408	Pharmacokinetic and Pharmacodynamic Comparison of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2007, 7, 888-898.	4.7	103
409	Lessons from the CAESAR Study: Calcineurin Inhibitors? Can't Live with Them and Can't Live without Them. <i>American Journal of Transplantation</i> , 2007, 7, 495-496.	4.7	6
410	Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. <i>American Journal of Transplantation</i> , 2007, 7, 1506-1514.	4.7	530
411	Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 1822-1831.	4.7	65
412	No Evidence for a Relationship Between Infiltrates in Renal Protocol Biopsies and Outcome. <i>American Journal of Transplantation</i> , 2007, 7, 2637-2638.	4.7	4
413	Suggested guidelines for reporting clinical results in transplantation trials. <i>Transplantation Reviews</i> , 2007, 21, 136-142.	2.9	1
414	Steroid- and calcineurin inhibitor free immunosuppression in kidney transplantation: state of the art and future developments. <i>World Journal of Urology</i> , 2007, 25, 325-332.	2.2	12

#	ARTICLE	IF	CITATIONS
415	Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. <i>Clinical Nephrology</i> , 2007, 67, 164-175.	0.7	15
416	Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A. <i>Clinical Immunology</i> , 2006, 119, 59-66.	3.2	3
417	FK506, transforming growth factor- $\beta$ 1 and mesangial matrix synthesis: Parallels and differences compared with cyclosporine A. <i>Cytokine</i> , 2006, 33, 59-65.	3.2	6
418	Effect of Mycophenolate Mofetil Monotherapy on T-Cell Functions and Inosine Monophosphate Dehydrogenase Activity in Patients Undergoing a Kidney Transplantation. <i>Transplantation Proceedings</i> , 2006, 38, 2292-2294.	0.6	10
419	Conversion to Enteric-Coated Mycophenolate Sodium From Various Doses of Mycophenolate Mofetil: Results of a Prospective International Multicenter Trial in Maintenance Renal Transplant Patients Receiving Cyclosporine. <i>Transplantation Proceedings</i> , 2006, 38, 2856-2859.	0.6	17
420	Reporting of Rejection after Renal Transplantation in Large Immunosuppressive Trials: Biopsy-Proven, Clinical, Presumed, or Treated Rejection?. <i>Transplantation</i> , 2006, 81, 655-659.	1.0	14
421	Three-Year Observational Follow-up of a Multicenter, Randomized Trial on Tacrolimus-Based Therapy with Withdrawal of Steroids or Mycophenolate Mofetil after Renal Transplant. <i>Transplantation</i> , 2006, 82, 55-61.	1.0	76
422	Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplant Patients Treated With Mycophenolate Mofetil: Review of the Literature. <i>Transplantation</i> , 2006, 82, 1004-1012.	1.0	65
423	FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1-Year, Randomized Controlled Trial in Europe and Australasia. <i>American Journal of Transplantation</i> , 2006, 6, 2912-2921.	4.7	145
424	FTY720 (fingolimod) in renal transplantation. <i>Clinical Transplantation</i> , 2006, 20, 17-24.	1.6	92
425	Improved diagnosis of early kidney allograft dysfunction by ultrasound with echo enhancer—a new method for the diagnosis of renal perfusion. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2921-2929.	0.7	51
426	Novel Mediators of FTY720 in Human Lymphocytes. <i>Transplantation</i> , 2005, 79, 492-495.	1.0	11
427	Influence of Everolimus on Steady-State Pharmacokinetics of Cyclosporine in Maintenance Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 781-791.	2.0	12
428	Corticosteroid-Free Immunosuppression with Tacrolimus, Mycophenolate Mofetil, and Daclizumab Induction in Renal Transplantation. <i>Transplantation</i> , 2005, 79, 807-814.	1.0	217
429	FTY720, a Novel Immunomodulator in de Novo Kidney Transplant Patients: Pharmacokinetics and Exposure-Response Relationship. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1268-1278.	2.0	34
430	Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1)-mediated pathway and vascular oxidative injury in older-age rat renal transplants. <i>Kidney International</i> , 2005, 67, 1583-1594.	5.2	15
431	Use of Neoral C2 monitoring: a European consensus. <i>Transplant International</i> , 2005, 18, 768-778.	1.6	59
432	Pharmacokinetic Principles of Immunosuppressive Drugs. <i>American Journal of Transplantation</i> , 2005, 5, 207-217.	4.7	59

#	ARTICLE	IF	CITATIONS
433	Proposal for Guidelines for Publication of Randomized Trials in the American Journal of Transplantation. American Journal of Transplantation, 2005, 5, 644-647.	4.7	8
434	Enteric-Coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF), it is Better to Have the Choice. American Journal of Transplantation, 2005, 5, 1165-1166.	4.7	4
435	Three-Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients. American Journal of Transplantation, 2005, 5, 2521-2530.	4.7	208
436	Effect of Pregnancy on Long-Term Kidney Function in Renal Transplant Recipients Treated with Cyclosporine and with Azathioprine. American Journal of Transplantation, 2005, 5, 2732-2739.	4.7	66
437	The use of contrast-enhanced US in renal transplant: first results and potential clinical benefit. European Radiology, Supplement, 2005, 15, e109-e116.	1.4	35
438	A systematic approach to managing pregnant dialysis patients—the importance of an intensified haemodiafiltration protocol. Nephrology Dialysis Transplantation, 2005, 20, 2537-2542.	0.7	90
439	Angiotensin II Type 1 Receptor Activating Antibodies in Renal-Allograft Rejection. New England Journal of Medicine, 2005, 352, 558-569.	27.0	760
440	Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy. Nephrology Dialysis Transplantation, 2005, 20, 220-222.	0.7	42
441	Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. Nephrology Dialysis Transplantation, 2005, 20, 319-328.	0.7	31
442	Limitations of C2 monitoring in renal transplant recipients. Nephrology Dialysis Transplantation, 2005, 20, 1463-1470.	0.7	23
443	Graft Function, Cardiovascular Risk Factors, and Sex Hormones in Renal Transplant Recipients on an Immunosuppressive Regimen of Everolimus, Reduced Dose of Cyclosporine, and Basiliximab. Transplantation Proceedings, 2005, 37, 1601-1604.	0.6	43
444	Safety and Efficacy After Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium: Results of a 1-Year Extension Study. Transplantation Proceedings, 2005, 37, 912-915.	0.6	21
445	Accurate Prediction of Kidney Allograft Outcome Based on Creatinine Course in the First 6 Months Posttransplant. Transplantation Proceedings, 2005, 37, 731-733.	0.6	6
446	Laparoscopic versus Open Donor Nephrectomy in Germany: Impact on Donor Health-Related Quality of Life and Willingness to Donate. Transplantation Proceedings, 2005, 37, 2011-2015.	0.6	31
447	Differences in Reporting of Acute Rejections Between American and European Publications of Large Immunosuppressive Trials Impair Comparability of Study Results. Transplantation Proceedings, 2005, 37, 2048-2050.	0.6	0
448	Sirolimus Dosage during and after Conversion from Calcineurin Inhibitor Therapy to Sirolimus in Chronic Kidney Transplant Patients. Kidney and Blood Pressure Research, 2004, 27, 186-190.	2.0	6
449	Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opinion on Pharmacotherapy, 2004, 5, 1333-1345.	1.8	84
450	The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrology Dialysis Transplantation, 2004, 19, 215-222.	0.7	41

#	ARTICLE	IF	CITATIONS
451	Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2606-2614.	0.7	41
452	The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2630-2633.	0.7	55
453	No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2846-2851.	0.7	8
454	MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 548-553.	2.4	72
455	FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury. <i>Kidney International</i> , 2004, 65, 1076-1083.	5.2	45
456	Reports of Large Immunosuppression Trials in Kidney Transplantation: Room for Improvement. <i>American Journal of Transplantation</i> , 2004, 4, 738-743.	4.7	30
457	Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2004, 4, 1869-1875.	4.7	229
458	Pre-Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 2045-2051.	4.7	138
459	Testosterone Concentrations and Sirolimus in Male Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2004, 4, 130-131.	4.7	87
460	Enteric-Coated Mycophenolate Sodium can be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1-Year Study. <i>American Journal of Transplantation</i> , 2004, 4, 237-243.	4.7	238
461	Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. <i>American Journal of Kidney Diseases</i> , 2004, 43, 923-926.	1.9	22
462	Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 330-340.	4.7	124
463	Impact of cyclosporine on the development of immunosuppressive therapy. <i>Transplantation Proceedings</i> , 2004, 36, S130-S134.	0.6	13
464	Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. <i>Transplantation Proceedings</i> , 2004, 36, S524-S527.	0.6	15
465	FTY720: early clinical experience. <i>Transplantation Proceedings</i> , 2004, 36, S544-S548.	0.6	19
466	FTY720 MEDIATES APOPTOSIS-INDEPENDENT LYMPHOPENIA IN HUMAN RENAL ALLOGRAFT RECIPIENTS: DIFFERENT EFFECTS ON CD62L+ AND CCR5+ T LYMPHOCYTES. <i>Transplantation</i> , 2004, 77, 1424-1432.	1.0	13
467	Calcium Channel Blockade and Preservation of Renal Graft Function in Cyclosporine-Treated Recipients: A Prospective Randomized Placebo-Controlled 2-Year Study. <i>Transplantation</i> , 2004, 78, 1204-1211.	1.0	79
468	Quality of Life of Living Kidney Donors in Germany: A Survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 Questionnaires. <i>Transplantation</i> , 2004, 78, 864-872.	1.0	97

#	ARTICLE	IF	CITATIONS
469	FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 702-713.	0.7	40
470	IMPACT OF DACLIZUMAB AND LOW DOSE CYCLOSPORINE IN COMBINATION WITH MYCOPHENOLATE MOFETIL AND STEROIDS ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2004, 78, 280-281.	1.0	2
471	PROBLEMS OF CYCLOSPORINE ABSORPTION PROFILING USING C2-MONITORING. <i>Transplantation</i> , 2004, 78, 457.	1.0	0
472	Pharmacokinetics of Intravenous, Single-Dose Tiotropium in Subjects with Different Degrees of Renal Impairment. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 163-172.	2.0	40
473	Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients. <i>American Journal of Transplantation</i> , 2003, 3, 846-854.	4.7	96
474	Old-for-Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool. <i>American Journal of Transplantation</i> , 2003, 3, 1434-1439.	4.7	111
475	“Old-for-Old” Cadaveric Renal Transplantation: Surgical Findings, Perioperative Complications and Outcome. <i>European Urology</i> , 2003, 44, 701-708.	1.9	56
476	Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 203-211.	2.4	156
477	The pharmacokinetics of pioglitazone in patients with impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 2003, 55, 368-374.	2.4	125
478	20-year experience with elderly donors in living renal transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 2855-2857.	0.6	16
479	Living donor Nephrectomy—No impact of genetic relationship. <i>Transplantation Proceedings</i> , 2003, 35, 2860-2862.	0.6	2
480	The immunosuppressive potential of misoprostol—efficacy and variability. <i>Clinical Immunology</i> , 2003, 109, 288-294.	3.2	6
481	Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. <i>Transplantation Proceedings</i> , 2003, 35, 2104-2105.	0.6	20
482	Impact of PGE1 on cyclosporine A induced up-regulation of TGF- $\beta$ 1, its receptors, and related matrix production in cultured mesangial cells. <i>Cytokine</i> , 2003, 22, 189-193.	3.2	8
483	Sirolimus and lymphocele formation after kidney transplantation: an immunosuppressive medication as co-factor for a surgical problem?. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 448-449.	0.7	24
484	Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 819-822.	0.7	159
485	<i>MDR1</i> Haplotypes Do Not Affect the Steady-State Pharmacokinetics of Cyclosporine in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1101-1107.	2.0	62
486	Gadolinium-enhanced three-dimensional magnetic resonance angiography versus conventional digital subtraction angiography: which modality is superior in evaluating living kidney donors?1. <i>Transplantation</i> , 2003, 76, 1000-1002.	1.0	26



#	ARTICLE	IF	CITATIONS
487	Evaluating candidates for kidney transplantation: some recommendations still lack convincing clinical evidence. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 621-622.	0.7	2
488	Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 470-476.	0.6	46
489	Cyclosporin C2hour monitoring after renal transplantation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 477-481.	0.6	4
490	Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 482-487.	0.6	9
491	Treating type 2 diabetes in renal insufficiency: the role of pioglitazone. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, 41, 488-491.	0.6	7
492	Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1310-1317.	0.7	42
493	Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1568-1577.	0.7	44
494	Recognition of Critical Situations from Time Series of Laboratory Results by Case-Based Reasoning. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2002, 9, 520-528.	4.4	19
495	Successful steroid withdrawal at the end of the 1st year after renal transplantation in mycophenolate mofetil-treated patients. <i>Transplantation Proceedings</i> , 2002, 34, 1700-1702.	0.6	4
496	Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up. <i>Transplantation Proceedings</i> , 2002, 34, 1703-1706.	0.6	12
497	Cyclosporine absorption profiling and therapeutic drug monitoring using c2 blood levels in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1738-1739.	0.6	18
498	Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 1594-1596.	0.6	4
499	Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. <i>Transplantation Proceedings</i> , 2002, 34, 1745-1747.	0.6	10
500	Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1748-1750.	0.6	24
501	Increased frequency of lymphoceles under treatment with sirolimus following renal transplantation: a single center experience. <i>Transplantation Proceedings</i> , 2002, 34, 1815-1816.	0.6	15
502	Relevance and meaning of prostate cancer in kidney transplantation. <i>Transplantation Proceedings</i> , 2002, 34, 2225-2226.	0.6	10
503	FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. <i>Transplantation Proceedings</i> , 2002, 34, 2242-2243.	0.6	7
504	Laparoscopic donor nephrectomy in Germany. <i>Transplantation Proceedings</i> , 2002, 34, 3099-3101.	0.6	9



#	ARTICLE	IF	CITATIONS
505	Effect of Food on Everolimus Absorption: Quantification in Healthy Subjects and a Confirmatory Screening in Patients with Renal Transplants. <i>Pharmacotherapy</i> , 2002, 22, 154-159.	2.6	75
506	Immunohistochemical double-staining of renal allograft tissue: critical assessment of three different protocols. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 648-654.	2.8	7
507	Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. <i>Hepatology</i> , 2002, 35, 466-477.	7.3	77
508	First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1073-1083.	6.1	257
509	Optimizing neoral therapeutic drug monitoring with cyclosporine trough (C0) and C2 concentrations in stable renal allograft recipients. <i>Transplantation Proceedings</i> , 2001, 33, 3102-3103.	0.6	8
510	Pharmacodynamic monitoring of lymphocyte proliferation and TGF- $\beta$ 1 expression at cyclosporine a (CyA) trough levels (C0) and 2 hours after intake (C2) of CyA in human renal allograft recipients. <i>Transplantation Proceedings</i> , 2001, 33, 3148-3150.	0.6	8
511	Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. <i>Transplantation Proceedings</i> , 2001, 33, 3234-3235.	0.6	37
512	Steroid withdrawal in long-term cyclosporine a treated patients using mycophenolate mofetil: a prospective randomized pilot study. <i>Transplantation Proceedings</i> , 2001, 33, 3250-3252.	0.6	4
513	Pharmacodynamic monitoring of mycophenolate mofetil in renal allograft recipients. <i>Transplantation Proceedings</i> , 2001, 33, 3313-3315.	0.6	8
514	Case-based reasoning algorithm for kidney transplant monitoring. <i>Transplantation Proceedings</i> , 2001, 33, 3331-3333.	0.6	1
515	Prostaglandin E1 inhibits cyclosporine A-induced upregulation of transforming growth factor-beta 1 in rat mesangial cells. <i>Transplantation Proceedings</i> , 2001, 33, 3342-3344.	0.6	2
516	Laparoscopic kidney harvesting for living donor kidney transplantation— one year follow-up of the initial 15 patients. <i>Transplantation Proceedings</i> , 2001, 33, 3791-3792.	0.6	4
517	CC chemokine receptor 5 and renal-transplant survival. <i>Lancet, The</i> , 2001, 357, 1758-1761.	13.7	283
518	Non-radioactive determination of inosine 5- $\alpha$ -monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. <i>Clinical Biochemistry</i> , 2001, 34, 543-549.	1.9	78
519	A Web-Based Electronic Patient Record System as a Means for Collection of Clinical Data. <i>Lecture Notes in Computer Science</i> , 2001, , 198-205.	1.3	3
520	PRACTICE VARIATIONS IN THE EVALUATION OF ADULT CANDIDATES FOR CADAVERIC KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2000, 70, 1492-1497.	1.0	33
521	Pharmacodynamic Monitoring of Mycophenolate Mofetil. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1213-6.	2.3	60
522	Age-matching in renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 696-700.	0.7	111

#	ARTICLE	IF	CITATIONS
523	TNF- $\alpha$ AND IL-1 $\beta$ INDUCE APOPTOSIS IN SUBCONFLUENT RAT MESANGIAL CELLS. EVIDENCE FOR THE INVOLVEMENT OF HYDROGEN PEROXIDE AND LIPID PEROXIDATION AS SECOND MESSENGERS. <i>Cytokine</i> , 2000, 12, 986-991.	3.2	65
524	Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. <i>American Journal of Kidney Diseases</i> , 2000, 35, e12.1-e12.5.	1.9	15
525	RE: SUCCESSFUL LIVING RELATED KIDNEY TRANSPLANTATION DESPITE RENAL ANGIOMYOLIPOMA IN SITU. <i>Journal of Urology</i> , 2000, 163, 924-924.	0.4	9
526	Renal failure from diabetic glomerulosclerosis three decades after allograft transplantation. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 974-976.	0.7	0
527	Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required?. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 1036-1038.	0.7	33
528	Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 694-703.	2.4	76
529	Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 251-261.	4.7	146
530	De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. <i>American Journal of Kidney Diseases</i> , 1999, 34, 556-559.	1.9	78
531	Treatment of acute c-ANCA $\alpha$ positive vasculitis with mycophenolate mofetil. <i>American Journal of Kidney Diseases</i> , 1999, 34, e9.1-e9.6.	1.9	28
532	Long-term investigation of hepatitis G virus infection in renal transplant recipients with and without hepatitis B and C co-infection. <i>Transplantation Proceedings</i> , 1999, 31, 1382-1383.	0.6	2
533	SUCCESSFUL LIVING RELATED KIDNEY TRANSPLANTATION DESPITE RENAL ANGIOMYOLIPOMA IN SITU. <i>Journal of Urology</i> , 1999, 162, 480-481.	0.4	15
534	HUMAN SAFETY AND PHARMACOLOGY OF FTY 720. <i>Transplantation</i> , 1999, 67, S153.	1.0	10
535	STEADY-STATE PHARMACOKINETICS AND TOLERABILITY OF RAD AND ITS INFLUENCE ON CYCLOSPORINE IN STABLE RENAL TRANSPLANT PATIENTS. <i>Transplantation</i> , 1999, 67, S160.	1.0	2
536	SUCCESSFUL STEROID WITHDRAWAL DURING THE FIRST YEAR AFTER RENAL TRANSPLANTION IN MYCOPHENOLATE MOFETIL AND CYCLOSPORINE TREATED PATIENTS. <i>Transplantation</i> , 1999, 67, S160.	1.0	4
537	HUMAN PHARMACOKINETICS OF FTY 720. <i>Transplantation</i> , 1999, 67, S204.	1.0	9
538	Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. <i>Transplant International</i> , 1999, 12, 283-287.	1.6	4
539	Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. <i>Transplant International</i> , 1998, 11, 53-57.	1.6	10
540	Conversion to Mycophenolate Mofetil for Chronic Progressive Deterioration of Renal Allograft Function: First Clinical Experiences in 44 Patients. <i>Transplantation Proceedings</i> , 1998, 30, 1190-1191.	0.6	14

#	ARTICLE	IF	CITATIONS
541	Tacrolimus Rescue Therapy in Late Rejection After Renal Transplantation: Outcome After 18 Months. Transplantation Proceedings, 1998, 30, 1238-1239.	0.6	2
542	Antibody therapy in steroid-resistant rejection. Transplantation Proceedings, 1998, 30, 1778-1779.	0.6	13
543	Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. Transplantation Proceedings, 1998, 30, 1780-1781.	0.6	3
544	Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. Transplantation Proceedings, 1998, 30, 2083-2085.	0.6	9
545	The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplantation Proceedings, 1998, 30, 2195-2197.	0.6	64
546	Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function. Transplantation Proceedings, 1998, 30, 2229.	0.6	2
547	Body composition and substrate oxidation in long-term survivors after transplantation of liver or kidney. Gastroenterology, 1998, 114, A1330.	1.3	0
548	Mycophenolate mofetil pharmacokinetics in renal transplant recipients on peritoneal dialysis. Transplant International, 1998, 11, 53-57.	1.6	5
549	Interleukin-6 expression after renal transplantation. Nephrology Dialysis Transplantation, 1997, 12, 753-759.	0.7	66
550	Differing proteinuria control with cyclosporin and tacrolimus. Lancet, The, 1997, 349, 330.	13.7	16
551	Hypertension in patients after renal transplantation. Transplantation Proceedings, 1997, 29, 209-211.	0.6	36
552	Interleukin-8 expression in patients after renal transplantation. American Journal of Kidney Diseases, 1997, 29, 871-880.	1.9	29
553	Glomerular epithelial cell products stimulate mesangial cell proliferation in culture. Kidney International, 1997, 52, 733-741.	5.2	11
554	The influence of age on outcome after renal transplantation. Geriatric Nephrology and Urology, 1997, 7, 137-146.	0.3	17
555	Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. Nephrology Dialysis Transplantation, 1996, 11, 165-172.	0.7	19
556	The diagnostic value of GM-CSF and IL-6 determinations in patients after renal transplantation. Transplant International, 1994, 7, 97-101.	1.6	11
557	Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney International, 1990, 38, 249-257.	5.2	179
558	Cytosorb® Rescue for COVID-19 Patients with Vasoplegic Shock (CytoResc): A Prospective, Open-Label, Randomised Controlled Pilot Study. SSRN Electronic Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
559	Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in de novo Kidney Transplant Patients Across Europe. <i>Transplant International</i> , 0, 35, .	1.6	9
560	Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	10
561	Patient-Reported Outcomes as Endpoints in Clinical Trials of Kidney Transplantation Interventions. <i>Transplant International</i> , 0, 35, .	1.6	13
562	Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	9
563	Surrogate Endpoints for Late Kidney Transplantation Failure. <i>Transplant International</i> , 0, 35, .	1.6	18
564	Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	8
565	Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation. <i>Transplant International</i> , 0, 35, .	1.6	6
566	Alloimmune Risk Stratification for Kidney Transplant Rejection. <i>Transplant International</i> , 0, 35, .	1.6	10